FDA Approves AOP Health’s Rapiblyk™ (Landiolol) for Atrial Fibrillation and Flutter in Critical Care
AOP Orphan Pharmaceuticals GmbH (AOP Health), based in Vienna, Austria, has announced that the U.S. Food and Drug Administration (FDA) has approved Rapiblyk™ (landiolol) for the treatment of supraventricular tachycardia (SVT), including atrial fibrillation and atrial flutter, in critical care…
Galderma’s Phase III OLYMPIA 1 Data Shows Nemolizumab Improves Prurigo Nodularis Symptoms
Galderma recently announced that the full results from the Phase III OLYMPIA 1 trial, which evaluated the efficacy and safety of nemolizumab in adults with moderate-to-severe prurigo nodularis, were published in JAMA Dermatology. The data from this trial, in conjunction…
QIAGEN Expands QIAstat-Dx with New Barcelona Site to Boost Infectious Disease and Precision Medicine Growth
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today revealed plans to relocate its QIAstat-Dx operations to a new facility in Esplugues de Llobregat, near Barcelona. This move is part of a multi-year investment aimed at expanding and strengthening the company’s…
Hippocratic AI Granted US Patent for Key Innovation in Healthcare LLM Safety
Hippocratic AI, the company pioneering the first safety-focused Large Language Model (LLM) for healthcare, has announced the issuance of its first patent, US Patent 12,142,371, granted by the US Patent Office this month. This patent covers key innovations integrated into…
EU Approves BeiGene’s TEVIMBRA for Advanced Esophageal and Gastric Cancers
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company set to rebrand as BeOne Medicines, today announced that the European Commission has approved TEVIMBRA® (tislelizumab) in combination with chemotherapy for the first-line treatment of esophageal squamous cell…
Aulos Bioscience Doses First Patient in Phase 2 Trial of Avelumab and AU-007 for NSCLC
Aulos Bioscience, an innovative immuno-oncology company focused on developing potentially groundbreaking IL-2 therapeutics to revolutionize cancer care, has announced the dosing of its first patient in a Phase 2 clinical trial. The trial evaluates the combination of AU-007, avelumab (a…
Zai Lab’s AUGTYRO® Added to China’s Reimbursement Drug List for ROS1+ NSCLC
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced that China’s National Healthcare Security Administration (NHSA) has updated its 2024 National Reimbursement Drug List (NRDL) to include several of the company’s medicines. These updates expand patient access to innovative treatments across…
88% of Type 2 Diabetics Would Monitor Glucose More Consistently If Their Doctor Is ‘Watching
The 2024 National Diabetes Care Survey, a comprehensive analysis of Type 2 diabetes patients in the U.S., highlights the growing impact of cellular remote patient monitoring (RPM)™ on diabetes management. The survey reveals that an increasing number of patients are…
Oxford Nanopore and UK Biobank to Create First Epigenetic Dataset for Cancer, Dementia, and Complex Diseases
Oxford Nanopore Technologies, a leader in advanced nanopore-based molecular sensing technology, has announced a groundbreaking collaboration with UK Biobank to create the world’s first large-scale, comprehensive epigenetic dataset. Utilizing Oxford Nanopore’s cutting-edge DNA/RNA sequencing technology, the project will map the…
Sarepta and Arrowhead Pharmaceuticals Announce Global Licensing Agreement for siRNA Programs
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, has announced an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR). Under this agreement, Sarepta will gain exclusive global rights to several…
Median Technologies to Showcase AI-Powered Lung Cancer Diagnostic eyonis™ LCS at RSNA 2024
Median Technologies (FR0011049824, ALMDT), a leading innovator in the development of artificial intelligence (AI)-powered medical devices for early cancer detection, is set to attend the Radiological Society of North America (RSNA) 2024 Annual Meeting, scheduled to take place in Chicago,…
Exelixis Provides Regulatory Update on Cabozantinib (CABOMETYX®) for Advanced Neuroendocrine Tumors
Exelixis, Inc. (Nasdaq: EXEL) announced that the U.S. Food and Drug Administration (FDA) has scheduled a discussion of the supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX®) at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. The sNDA…